Jeffrey S. Wefel, Ph.D. - Publications

Affiliations: 
2002 University of Houston, Houston, TX, United States 
Area:
Alzheimer's disease

70 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Day J, Yust-Katz S, Cachia D, Wefel J, Katz LH, Tremont I, Bulbeck H, Armstrong T, Rooney AG. Interventions for the management of fatigue in adults with a primary brain tumour. The Cochrane Database of Systematic Reviews. 4: CD011376. PMID 27074263 DOI: 10.1002/14651858.CD011376.pub2  0.56
2016 Noll KR, Ziu M, Weinberg JS, Wefel JS. Neurocognitive functioning in patients with glioma of the left and right temporal lobes. Journal of Neuro-Oncology. PMID 27022915 DOI: 10.1007/s11060-016-2114-0  0.56
2016 Blakeley JO, Coons SJ, Corboy JR, Leidy NK, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro-Oncology. 18: ii13-ii20. PMID 26989128 DOI: 10.1093/neuonc/nov291  0.56
2016 Wefel JS, Noll KR, Scheurer ME. Neurocognitive functioning and genetic variation in patients with primary brain tumours. The Lancet. Oncology. 17: e97-e108. PMID 26972863 DOI: 10.1016/S1470-2045(15)00380-0  0.56
2016 Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Liu MC, Lowe A, Agar NY, Ryabin N, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26834058 DOI: 10.1200/JCO.2015.63.0343  0.56
2015 Noll KR, Weinberg JS, Ziu M, Wefel JS. Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes. Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists. PMID 26537777 DOI: 10.1093/arclin/acv064  0.56
2015 Noll KR, Wefel JS. Response to "From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function". Neuro-Oncology. 17: 1421-2. PMID 26395063 DOI: 10.1093/neuonc/nov176  0.56
2015 Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M, Castel H. Impact of Cancer and Its Treatment on Cognitive Function: Advances in Research from the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. Journal of Pain and Symptom Management. PMID 26344551 DOI: 10.1016/j.jpainsymman.2015.06.019  0.56
2015 Noll KR, Weinberg JS, Ziu M, Benveniste RJ, Suki D, Wefel JS. Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma. Neurosurgery. PMID 26317672 DOI: 10.1227/NEU.0000000000000987  0.56
2015 Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Conrad CA, Gilbert MR, Armstrong TS, Bondy ML, Wefel JS. Genetic Modulation of Neurocognitive Function in Glioma Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3340-6. PMID 25904748 DOI: 10.1158/1078-0432.CCR-15-0168  0.56
2015 Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. Ca: a Cancer Journal For Clinicians. 65: 123-38. PMID 25483452 DOI: 10.3322/caac.21258  0.56
2015 Noll KR, Sullaway C, Ziu M, Weinberg JS, Wefel JS. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro-Oncology. 17: 580-7. PMID 25227126 DOI: 10.1093/neuonc/nou233  0.56
2014 Schagen SB, Klein M, Reijneveld JC, Brain E, Deprez S, Joly F, Scherwath A, Schrauwen W, Wefel JS. Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions. Ejc Supplements : Ejc : Official Journal of Eortc, European Organization For Research and Treatment of Cancer ... [Et Al.]. 12: 29-40. PMID 26217164 DOI: 10.1016/j.ejcsup.2014.03.003  0.56
2014 Gilbert MR, Dignam J, Pugh S, Armstrong TS, Wefel JS, Aldape K, Stupp R, Hegi M, Won M, Curran WJ, Mehta MP. Reply to M.C. Chamberlain. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1634-5. PMID 24752060 DOI: 10.1200/JCO.2013.54.9717  0.56
2014 Wefel JS, Kornet RL, Schagen SB. Systemically treated breast cancer patients and controls: an evaluation of the presence of noncredible performance. Journal of the International Neuropsychological Society : Jins. 20: 357-69. PMID 24607070 DOI: 10.1017/S1355617714000022  0.56
2014 Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The New England Journal of Medicine. 370: 699-708. PMID 24552317 DOI: 10.1056/NEJMoa1308573  0.56
2014 Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA, Hoekstra HJ, Hoekstra-Weebers JEHM, Gritz ER. A prospective study of cognitive function in men with non-seminomatous germ cell tumors Psycho-Oncology. 23: 626-633. PMID 24339329 DOI: 10.1002/pon.3453  0.56
2014 Wefel JS, Schagen SB. Cognitive complaints after breast cancer treatments: Examining the relationship with neuropsychological test performance Breast Diseases. 25: 92-93. DOI: 10.1016/j.breastdis.2014.01.026  0.56
2013 Schagen SB, Wefel JS. Chemotherapy-related changes in cognitive functioning. Ejc Supplements : Ejc : Official Journal of Eortc, European Organization For Research and Treatment of Cancer ... [Et Al.]. 11: 225-32. PMID 26217131 DOI: 10.1016/j.ejcsup.2013.07.007  0.56
2013 Johnson DR, Wefel JS. Relationship between cognitive function and prognosis in glioblastoma. Cns Oncology. 2: 195-201. PMID 25057978 DOI: 10.2217/cns.13.5  0.56
2013 Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer. 119: 4188-95. PMID 24105672 DOI: 10.1002/cncr.28323  0.56
2013 Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4076-84. PMID 24101048 DOI: 10.1200/JCO.2013.49.6067  0.56
2013 Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4085-91. PMID 24101040 DOI: 10.1200/JCO.2013.49.6968  0.56
2013 Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. The Lancet. Oncology. 14: e407-16. PMID 23993385 DOI: 10.1016/S1470-2045(13)70308-5  0.56
2013 Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, ... ... Wefel JS, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. The Lancet. Oncology. 14: e396-406. PMID 23993384 DOI: 10.1016/S1470-2045(13)70311-5  0.56
2013 Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology. 15: 1429-37. PMID 23956241 DOI: 10.1093/neuonc/not114  0.56
2013 Welsh JW, McGovern SL, Wefel JS, Komaki R, Brown PD, Soh HE. Reply to v.R. Bhatt et Al and m.C. Chamberlain. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3165-6. PMID 23943829 DOI: 10.1200/JCO.2013.50.7160  0.56
2013 Kesler SR, Wefel JS, Hosseini SM, Cheung M, Watson CL, Hoeft F. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proceedings of the National Academy of Sciences of the United States of America. 110: 11600-5. PMID 23798392 DOI: 10.1073/pnas.1214551110  0.56
2013 Kesler SR, Watson C, Koovakkattu D, Lee C, O'Hara R, Mahaffey ML, Wefel JS. Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging and Behavior. 7: 501-10. PMID 23536015 DOI: 10.1007/s11682-013-9228-1  0.56
2013 Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 895-902. PMID 23341526 DOI: 10.1200/JCO.2011.40.1174  0.56
2012 Johnson DR, Sawyer AM, Meyers CA, O'Neill BP, Wefel JS. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro-Oncology. 14: 808-16. PMID 22508762 DOI: 10.1093/neuonc/nos082  0.56
2012 Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Current Neurology and Neuroscience Reports. 12: 267-75. PMID 22453825 DOI: 10.1007/s11910-012-0264-9  0.56
2012 Armstrong TS, Wefel JS, Gning I, Acquaye A, Vera-Bolanos E, Gilbert MR, Cleeland CS, Mendoza T. Congruence of primary brain tumor patient and caregiver symptom report. Cancer. 118: 5026-37. PMID 22415423 DOI: 10.1002/cncr.27483  0.56
2012 Schapiro R, Ferson D, Prabhu SS, Tummula S, Wefel J, Rao G. A technique for mapping cortical areas associated with speech arrest Stereotactic and Functional Neurosurgery. 90: 118-123. PMID 22398728 DOI: 10.1159/000335500  0.56
2012 Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, Wefel JS. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. Journal of Neuro-Oncology. 107: 165-74. PMID 21964738 DOI: 10.1007/s11060-011-0723-1  0.56
2011 Wu AS, Witgert ME, Lang FF, Xiao L, Bekele BN, Meyers CA, Ferson D, Wefel JS. Neurocognitive function before and after surgery for insular gliomas. Journal of Neurosurgery. 115: 1115-25. PMID 21905800 DOI: 10.3171/2011.8.JNS11488  0.56
2011 Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 660-8. PMID 21558074 DOI: 10.1093/neuonc/nor024  0.56
2011 van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. The Lancet. Oncology. 12: 583-93. PMID 21474379 DOI: 10.1016/S1470-2045(11)70057-2  0.56
2011 Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. The Lancet. Oncology. 12: 703-8. PMID 21354373 DOI: 10.1016/S1470-2045(10)70294-1  0.56
2011 Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology. 13: 353-61. PMID 21310734 DOI: 10.1093/neuonc/noq203  0.56
2011 Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JEHM, Shahani L, Gritz ER. Cognitive impairment in men with testicular cancer prior to adjuvant therapy Cancer. 117: 190-196. PMID 20737560 DOI: 10.1002/cncr.25298  0.56
2011 Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics. 79: 1487-95. PMID 20399573 DOI: 10.1016/j.ijrobp.2009.12.061  0.56
2011 Grosshans DR, Wefel JS. Catechol-o-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors: Small BJ, Rawson KS, Walsh E, et al (Univ of South Florida, Tampa, FL; Univ of Kentucky College of Medicine, Lexington; Et al) Cancer 117:1369-1376, 2011 Breast Diseases. 22: 411-412. DOI: 10.1016/j.breastdis.2011.10.031  0.56
2011 Wefel JS, Meyers CA. Reply to acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer Cancer. 117: 1103. DOI: 10.1002/cncr.25703  0.56
2010 Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 116: 3348-56. PMID 20564075 DOI: 10.1002/cncr.25098  0.56
2010 Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Whole-brain irradiation for patients with brain metastases: still the standard of care - Authors' reply The Lancet Oncology. 11: 223. DOI: 10.1016/S1470-2045(10)70011-5  0.56
2009 Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, Morris GS, Dong W, Jackson E, Weaver S, Gantela S, Evans DB, Grubbs EG, Lee JE. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism. Surgery. 146: 1116-22. PMID 19879613 DOI: 10.1016/j.surg.2009.09.034  0.56
2009 Benge JF, Perrier ND, Massman PJ, Meyers CA, Kayl AE, Wefel JS. Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy. Journal of the International Neuropsychological Society : Jins. 15: 1002-11. PMID 19807940 DOI: 10.1017/S1355617709990695  0.56
2009 Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. The Lancet. Oncology. 10: 1037-44. PMID 19801201 DOI: 10.1016/S1470-2045(09)70263-3  0.56
2009 Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA. Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists. 24: 689-98. PMID 19767298 DOI: 10.1093/arclin/acp060  0.56
2008 Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy Oncologist. 13: 1285-1295. PMID 19019972 DOI: 10.1634/theoncologist.2008-0130  0.56
2008 Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychology Review. 18: 121-31. PMID 18415683 DOI: 10.1007/s11065-008-9058-x  0.56
2008 Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology. 10: 208-15. PMID 18316473 DOI: 10.1215/15228517-2007-059  0.56
2008 Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 623-9. PMID 17974553 DOI: 10.1093/annonc/mdm500  0.56
2008 Smith JA, Wefel JS. Neurocognitive testing in clinical trials Cognition and Cancer. 320-328. DOI: 10.1017/CBO9780511545900.024  0.56
2008 Wefel JS, Collins R, Kayl AE. Cognitive dysfunction related to chemotherapy and biological response modifiers Cognition and Cancer. 97-114. DOI: 10.1017/CBO9780511545900.009  0.56
2008 Kayl AE, Collins R, Wefel JS. Neuropsychological assessment of adults with cancer Cognition and Cancer. 44-55. DOI: 10.1017/CBO9780511545900.006  0.56
2007 Mittendorf EA, Wefel JS, Meyers CA, Doherty D, Shapiro SE, Lee JE, Evans DB, Perrier ND. Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 13: 338-44. PMID 17669708 DOI: 10.4158/EP.13.4.338  0.56
2007 Chang EL, Wefel JS, Maor MH, Hassenbusch SJ, Mahajan A, Lang FF, Woo SY, Mathews LA, Allen PK, Shiu AS, Meyers CA. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery. 60: 277-83; discussion 2. PMID 17290178 DOI: 10.1227/01.NEU.0000249272.64439.B1  0.56
2006 Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: effects, potential mechanisms, and management. American Journal of Therapeutics. 13: 362-9. PMID 16858172 DOI: 10.1097/00045391-200607000-00013  0.56
2005 Heflin LH, Meyerowitz BE, Hall P, Lichtenstein P, Johansson B, Pedersen NL, Gatz M. Re: Cancer as a risk factor for dementia: a house built on shifting sand. Journal of the National Cancer Institute. 97: 1550-1; author reply. PMID 16234571 DOI: 10.1093/jnci/dji331  0.56
2005 Wefel JS, Meyers CA. Cancer as a risk factor for dementia: a house built on shifting sand. Journal of the National Cancer Institute. 97: 788-9. PMID 15928294 DOI: 10.1093/jnci/dji167  0.56
2004 Atchison TB, Sander AM, Struchen MA, High WM, Roebuck TM, Contant CF, Wefel JS, Novack TA, Sherer M. Relationship between neuropsychological test performance and productivity at 1-year following traumatic brain injury. The Clinical Neuropsychologist. 18: 249-65. PMID 15587672 DOI: 10.1080/13854040490501475  0.56
2004 Maruff P, Falleti MG, Collie A, Wefel JS, Meyers CA, Davis RN. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial [2] (multiple letters) Cancer. 101: 2143-2145. PMID 15382092 DOI: 10.1002/cncr.20601  0.56
2004 Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer. 101: 466-75. PMID 15274059 DOI: 10.1002/cncr.20393  0.56
2004 Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 100: 2292-9. PMID 15160331 DOI: 10.1002/cncr.20272  0.56
2004 Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. British Journal of Cancer. 90: 1691-6. PMID 15150608 DOI: 10.1038/sj.bjc.6601772  0.56
2003 Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 3557-8. PMID 12913103 DOI: 10.1200/JCO.2003.07.080  0.56
1999 Wefel JS, Hoyt BD, Massma PJ. Neuropsychological functioning in depressed versus nondepressed participants with Alzheimer's disease. The Clinical Neuropsychologist. 13: 249-57. PMID 10726596 DOI: 10.1076/clin.13.3.249.1746  0.56
1997 Suhr J, Tranel D, Wefel J, Barrash J. Memory performance after head injury: contributions of malingering, litigation status, psychological factors, and medication use. Journal of Clinical and Experimental Neuropsychology. 19: 500-14. PMID 9342686 DOI: 10.1080/01688639708403740  0.56
Show low-probability matches.